Abstract
Social distancing is an effective population-level mitigation strategy to prevent COVID19 propagation but it does not reduce the number of susceptible individuals and bears severe economic and psychological consequences. A vaccine has recently been developed but its deployment will be limited and not immediate. Designing an optimal combination of these two intervention strategies is a priority, but a mechanistic understanding of the interplay between these strategies is missing. To tackle this challenge we developed an age-structured deterministic model in which vaccines are deployed during the pandemic to individuals who, in the eye of public health, are susceptible (do not show symptoms). The model allows for flexible and dynamic prioritization strategies with shifts between target groups. We find that social distancing applied uniformly to all ages and with vaccination targeted towards adults (20-59) or elderly (60+) work in synergism but up to a threshold beyond which vaccination is not efficient. The inefficiency threshold can be eliminated by targeting social distancing at the age groups that are not vaccinated and the optimal strategy is to prioritize vaccines to elderly. Nevertheless, while vaccination reduces hospitalizations, it does not affect the time it takes to eliminate the virus from the population, which is affected only by social distancing. Finally, the same reduction in hospitalization can be achieved via different combination of strategies, giving decision makers flexibility in choosing public health policies. Our study provides insights into the factors that affect vaccination success and provides methodology to test different intervention strategies in a way that will align with ethical guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Ministry of Science \& Technology, Israel (grant no. 3-16893).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data we use originates from publicly available resources, such as academic literature or online epidemiological sources. We do not use any clinical data that requires IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This is a simulation study. Code will be published upon acceptance in the peer-reviewed journal